Medpace (NSDQ:MEDP) yesterday said affiliates of Cinven Capital Management are launching a secondary offering of 4 million shares of its common stock at $31.50 per share, for gross proceeds of $126 million – not including an underwriter’s option worth another $18.9 million. The offering includes a 30-day underwriters option to purchase an additional 600,000 shares, Cincinnati-based […]
Contract research organization Medpace (NSDQ:MEDP) said yesterday that its initial public offering closed after raising more than $185 million, including an underwriter’s over-allotment that added more than $24 million to the IPO. Cincinnati-based Medpace said it floated 8.05 million shares at $23 apiece, including the 1.05-million-share over-allotment, netting about $173.6 million for the CRO. The proceeds are earmarked […]
Ximedica said today that SV Life Sciences picked up a majority interest in the Providence, R.I.-based medical device development company from co-founders Stephen Lane and Aidan Petrie for an undisclosed amount.
There’s a special sauce in the recipe Ora Inc. uses to run clinical trials for ophthalmology devices and drugs that can reduce the time needed for a study from 6 months to 2 days: The eye care practice started by Ora founder Dr. Mark Abelson.
An ophthalmologist and optometric scientist and fellow at the Mass. Eye & Ear Infirmary, Abelson founded Andover Eye in 1978, his son Stuart Abelson – now Andover, Mass.-based Ora’s CEO – told MassDevice.com.